[HTML][HTML] Newly approved and investigational drugs for motor symptom control in Parkinson's disease
DG Di Luca, NGD Reyes, SH Fox - Drugs, 2022 - Springer
Motor symptoms are a core feature of Parkinson's disease (PD) and cause a significant
burden on patients' quality of life. Oral levodopa is still the most effective treatment, however …
burden on patients' quality of life. Oral levodopa is still the most effective treatment, however …
[HTML][HTML] Drugs targeting adenosine signaling pathways: A current view
B Kutryb-Zając, A Kawecka, K Nasadiuk… - Biomedicine & …, 2023 - Elsevier
Adenosine is an endogenous nucleoside that regulates many physiological and
pathological processes. It is derived from either the intracellular or extracellular …
pathological processes. It is derived from either the intracellular or extracellular …
[HTML][HTML] Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects
E Dewaeles, K Carvalho, S Fellah… - The Journal of …, 2022 - Am Soc Clin Investig
Cisplatin is a potent chemotherapeutic drug that is widely used in the treatment of various
solid cancers. However, its clinical effectiveness is strongly limited by frequent severe …
solid cancers. However, its clinical effectiveness is strongly limited by frequent severe …
[HTML][HTML] Involvement of adenosine signaling pathway in migraine pathophysiology: a systematic review of preclinical studies
Background Adenosine is a purinergic signaling molecule with a wide range of
physiological functions including anti-and pronociceptive properties. Adenosine receptors …
physiological functions including anti-and pronociceptive properties. Adenosine receptors …
[HTML][HTML] A2A adenosine receptor antagonists in neurodegenerative diseases
Background: Alzheimer's disease (AD) is the most common form of dementia worldwide,
with approximately 6 million cases reported in America in 2020. The clinical signs of AD …
with approximately 6 million cases reported in America in 2020. The clinical signs of AD …
[HTML][HTML] Pathophysiological Role and Medicinal Chemistry of A2A Adenosine Receptor Antagonists in Alzheimer's Disease
The A2A adenosine receptor is a protein belonging to a family of four GPCR adenosine
receptors. It is involved in the regulation of several pathophysiological conditions in both the …
receptors. It is involved in the regulation of several pathophysiological conditions in both the …
[HTML][HTML] Methylxanthines and neurodegenerative diseases: an update
Methylxanthines (MTX) are purine derived xanthine derivatives. Whereas naturally occurring
methylxanthines like caffeine, theophylline or theobromine are widely consumed in food …
methylxanthines like caffeine, theophylline or theobromine are widely consumed in food …
[HTML][HTML] In silico studies of natural product-like caffeine derivatives as potential MAO-B inhibitors/AA2AR antagonists for the treatment of Parkinson's disease
Y Boulaamane, MAA Ibrahim, MR Britel… - Journal of Integrative …, 2022 - degruyter.com
Parkinson's disease is considered the second most frequent neurodegenerative disease. It
is described by the loss of dopaminergic neurons in the mid-brain. For many decades, L …
is described by the loss of dopaminergic neurons in the mid-brain. For many decades, L …
Medicinal chemistry of P2 and adenosine receptors: Common scaffolds adapted for multiple targets
KA Jacobson, AP IJzerman, CE Müller - Biochemical pharmacology, 2021 - Elsevier
Abstract Prof. Geoffrey Burnstock originated the concept of purinergic signaling. He
demonstrated the interactions and biological roles of ionotropic P2X and metabotropic P2Y …
demonstrated the interactions and biological roles of ionotropic P2X and metabotropic P2Y …
In vitro pharmacological profile of KW-6356, a novel adenosine A2A receptor antagonist/inverse agonist
Y Ohno, M Suzuki, H Asada, T Kanda, M Saki… - Molecular …, 2023 - ASPET
KW-6356 is a novel adenosine A2A (A2A) receptor antagonist/inverse agonist, and its
efficacy as monotherapy in Parkinson's disease (PD) patients has been reported …
efficacy as monotherapy in Parkinson's disease (PD) patients has been reported …